Additionally, EFHD2 activates the NOX4-ROS-ABCC1 signaling pathway to reduce intracellular cisplatin levels, thereby conferring cisplatin resistance on NSCLC cells [11]. The gene discussed is NOX4; the disease is non-small cell lung carcinoma.